Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology

BACKGROUND AND OBJECTIVES: Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID‐19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is not transmissible by transfusion, but bloodborne pathogens...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemura, Susan, Hartson, Lindsay, Dutt, Taru S., Henao‐Tamayo, Marcela, Goodrich, Raymond, Marschner, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251479/
https://www.ncbi.nlm.nih.gov/pubmed/33835489
http://dx.doi.org/10.1111/vox.13108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251479/
https://www.ncbi.nlm.nih.gov/pubmed/33835489
http://dx.doi.org/10.1111/vox.13108

Ejemplares similares